Ceftriaxone versus β-lactams with antipseudomonal activity for empirical, combined antibiotic therapy in febrile neutropenia: A meta- analysis

Supportive Care in Cancer

Volumn 8, Issue 4, 2000, Pages 293-301

  Furno, Paolo ^a   Dionisi, Maria Stella ^a   Bucaneve, Giampaolo ^a   Menichetti, Francesco ^b   Del Favero, Albano ^a  

^a POLICLINICO MONTELUCE   (Italy)

^b CISANELLO HOSPITAL   (Italy)

Author keywords

Antipseudomonal lactam; Ceftriaxone; Fever; Meta analysis; Neutropenia

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTRIAXONE; UREIDOPENICILLIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTEREMIA; CANCER PATIENT; CAUSE OF DEATH; DRUG MIXTURE; FEBRILE NEUTROPENIA; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; TREATMENT OUTCOME;

EID: 0033920609     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200000105     Document Type: Review

References (28)

1. Berlin JA, Laird NM, Sacks HS, Chalmers TC (1989) A comparison of statistical methods for combining event rates from clinical trials. Stat Med 8:141-151
2. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 64:328-340
3. Chalmers TC, Smith H, Blackburn B, et al (1981) A method for assessing the quality of a randomized control trial. Control Clin Trials 2:31-49
4. Charnas R, Ridolfi Luthi A, Ruch W (Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children) (1997) Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Pediatr Infect Dis J 16:346-353
5. Cook DJ, Sackett DL, Spitzer WO (1995) Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam consultation on meta-analysis. J Clin Epidemiol 48:167-171
6. Del Favero A, Bucaneve G, Menichetti F (1995) Empiric monotherapy in neutropenia: a realistic goal? Scand J Infect Dis Suppl 96:34-37
7. Eysenck HJ (1994) (1994) Meta-analysis and its problems. (Systematic reviews) Br Med J 309:789-792
8. Fauser A, Lang E, Kochling G, Daschner FD (1994) A randomized clinical trial of ceftriaxone and teicoplanin versus ceftazidime and teicoplanin as antibiotic therapy in febrile neutropenic cancer patients and bone marrow transplant recipients. Infection 4:271-275
9. Gibson J, Johnson L, Snowdon L, et al (1993) Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol 58:63-72
10. GIMEMA Infection Program (1991) Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 115:7-12
11. Hughes WT, Armstrong D, Bodey GP, et al (1990) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161:381-396
12. IATCG-EORTC (1993) Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 7:584-593
13. Klastersky J (1993) Empirical antibiotic therapy in neutropenic cancer patients. Eur J Cancer [A] 29 [Suppl 1]:S6-10
14. Klastersky J (1993) Febrile neutropenia. Support Care Cancer 1:233-239
15. Klastersky J, Zinner SH, Calandra T, et al (1988) Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 24 [Suppl 1]:S35-S45
16. L'Abbe KA, Detsky AS, O'Rourke K (1987) Meta-analysis in clinical research. Ann Intern Med 107:224-233
17. Leoni F, Ciolli S, Pascarella A, Fanci R, Caporale R, Rossi Ferrini PL (1993) Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients. Chemotherapy 39:147-152
18. Liu CY, Wang FD (1989) A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients. Chemotherapy 35 [Suppl 2]:16-22
19. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748
20. Menichetti F, Martino P, Bucaneve G and the GIMEMA Infection Program (1994) Teicoplanin versus vancomycin as initial, combined empirical antibiotic therapy in febrile neutropenic patients with hematologic malignancies. Antmicrob Agents Chemother 38:2041-2046
21. Pizzo PA (1995) Empiric therapy and prevention of infection in the immunocompromised host. In: Mandell GL, Douglas GR, Bennett JE (eds) Principles and practice of infectious diseases, 4th edn. Churchill Livingstone, New York, pp 2686-2696
22. Powe NR, Kinnison ML. Steinberg EP (1989) Quality assessment of randomized controlled trials of contrast media. Radiology 170:377-380
23. Sacks HS, Berrier J, Reitman D, Berk A, Chalmers T (1987) Meta-analyses of randomized controlled trials. N Engl J Med 316:450-455
24. Schmid L, Jeschko M, Wilder-Smith C et al (1991) Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia. Chemotherapy 37:346-352
25. Thacker SB (1988) Meta-analysis. A quantitative approach to research integration. JAMA 259:1685-1689
26. Victor N (1995) The challenge of meta-analysis: discussion, indications and contra-indications for meta-analysis. J Clin Epidemiol 48:5-8
27. Yataganas X, Rombos Y, Vayopoulos G, Meletis J, Avlami A (1991) Randomized clinical trial comparing ceftriaxone/amikacin versus ceftazidime/ amikacin as initial therapy of febrile episodes in neutropenic patients. Chemotherapy 37:376-381
28. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371